PRODUCTS
RAYALDEE®
Calcifediol extended-release capsules
An extended-release formulation of calcifediol and a key product in NICOYA's regional collaboration with OPKO.
Explore the product
ABOUT RAYALDEE
Ingredient and formulation.
- Ingredient
- Calcifediol [25-hydroxyvitamin D₃]
- Formulation and strength
- Oral extended-release capsules; strength: 30 μg. See prescribing information.
Calcifediol is a precursor of active vitamin D and undergoes further activation before acting through these pathways.
Extended-release formulation
Calcifediol is delivered in an oral extended-release capsule.
Further activation
It is converted to calcitriol, primarily in the kidney.
Receptor-mediated activity
The active form acts through vitamin D receptor pathways involved in parathyroid hormone regulation.

Extended-release conceptCLINICAL STUDIES
Measures observed in clinical studies.
Two U.S. phase 3 trials enrolled 429 adults, and a Chinese phase 3 trial enrolled 100. Participants had stage 3 or 4 CKD, secondary hyperparathyroidism and vitamin D insufficiency; treatment lasted 26 weeks.
Vitamin D status
Patients with serum total 25(OH)D ≥ 30 ng/mL
View chart values
| Study / analysis | RAYALDEE | Placebo |
|---|---|---|
| U.S. · 3001 | 80.2% | 2.8% |
| U.S. · 3002 | 83.3% | 6.8% |
| China · ITT | 90.9% | 9.4% |
| China · PPS | 95.1% | 11.1% |
iPTH response in SHPT
Patients with an iPTH reduction ≥ 30% from baseline
View chart values
| Study / analysis | RAYALDEE | Placebo |
|---|---|---|
| U.S. · 3001 | 32.6% | 8.3% |
| U.S. · 3002 | 34.0% | 6.9% |
| China · ITT | 53.0% | 6.3% |
| China · PPS | 55.7% | 7.4% |
Study 3003 · Open-label extension
Patients with an iPTH reduction ≥ 30% at 52 weeks; both groups received ERC.
- Continued ERC
- 49.2%
- Placebo switched to ERC
- 33.0%
For the primary endpoint of at least 30% iPTH reduction, the U.S. trials reported 33% versus 8% and 34% versus 7%, RAYALDEE versus placebo. The Chinese ITT result was 53.0% versus 6.3%.
Study results do not guarantee individual outcomes or establish approval in mainland China. Locally approved labeling governs use.
Global regulatory progress
Approval records and jurisdictions
United States · Canada · Germany · Ireland · Italy · Spain · Denmark · Sweden · Norway · Portugal · Netherlands · Switzerland · United Kingdom · Israel · Macao, China · Hong Kong, China
Regional approvals do not imply uniform indications or uses. Refer to locally approved documents for applicable information.
USE AND SAFETY
Use and safety.
- Indication
- For treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency (serum total 25-hydroxyvitamin D below 30 ng/mL). See prescribing information.
- Limitations of use
- Not indicated for stage 5 chronic kidney disease or end-stage renal disease on dialysis. Safety and effectiveness in pediatric patients have not been established. Healthcare professionals should assess and monitor calcium, phosphorus, total 25-hydroxyvitamin D and intact parathyroid hormone (iPTH) according to the labeling. For contraindications, warnings and other safety information, see prescribing information.
Medicine information differs by jurisdiction. Refer to locally approved labeling and medical professionals for eligible patients, limitations and safety information. This website does not offer sales, prescriptions, individual medication advice or medical care.